5 Oversold Biotech Stocks to Buy

Page 1 of 5

In this article, we will take a look at the 5 oversold biotech stocks to buy. To read our analysis of the recent trends and market activity, you can go to the 10 Oversold Biotech Stocks to Buy.

5. Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

14-day RSI as of July 25: 26.79

Number of Hedge Fund Holders: 23

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities for treatment of disease areas with significant unmet medical needs.

Rusfertide is the lead product candidate of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) currently in a global Phase 3 stage of development. The global Phase 3 VERIFY study of Rusfertide in polycythemia vera, a type of blood cancer, is ongoing.

On July 4, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced positive topline results from the Phase 2b FRONTIER 1 clinical trial evaluating JNJ-2113 for patients with moderate to severe plaque psoriasis.

The drug was discovered using the discovery platform of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and is being further developed by Johnson & Johnson (NYSE:JNJ) which holds exclusive rights to develop JNJ-2113 in Phase 2 clinical trials and beyond. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is eligible for up to $855 million in various future milestone payments including royalties on potential worldwide sales.

Page 1 of 5